Clinical trials: Dexamethasone Administration
Primary Amyloidosis of Light Chain Type
Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis
The aim of the study is to evaluate the safety and efficacy of Pomalidomide and Dexamethasone in patients who did not achieve a complete response after initial treatment with both an alkylating agent (Melphalan or…
- Trial name
- NCT01510613
- Testing
- Pomalidomide and Dexamethasone
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Multiple Myeloma
Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD)
Primary objective: Compare the complete remission (CR) rates (i.e., the true CR, with negative immunofixation) achieved with either four courses of VD or four courses of VTD.
- Trial name
- NCT00910897
- Testing
- Velcade-Dexamethasone, Velcade-Thalidomide-Dexamethasone
- Where
- 56 sites in Belgium, France
- Volunteers
- 205 people
- Sponsor
- Intergroupe Francophone du Myelome
Nausea and Vomiting Caused by Chemotherapy
Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Gemcitabine Plus Paclitaxel
The goal of this clinical trial is to learn if auricular point stimulation plus dexamethasone works to effectively prevent or suppress nausea and vomiting caused by gemcitabine combined with paclitaxel protein-bound in pancreatic…
- Trial name
- ADGP (NCT07537660)
- Testing
- Auricular point stimulation plus dexamethasone
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Purpura, Thrombocytopenic, Idiopathic
Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia
Patients above age 18 with a first episode of immune thrombocytopenia are randomized 1:1 between 2-4 weeks of daily prednisone (1 mg/kg/d) with subsequent dose tapering (arm A) and six 3-week cycles of pulsed dexamethasone (0.6…
- Trial name
- EIS2002 (NCT02334813)
- Testing
- Prednisone, Dexamethasone
- Volunteers
- 26 people
- Sponsor
- University Hospital, Essen
Myeloma Multiple
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
This study is being done to answer the following question: Can the addition of daratumumab-hyaluronidase to the usual treatment of bortezomib and dexamethasone improve kidney function in patients who are newly diagnosed with…
- Trial name
- NCT07085728
- Testing
- Cyclophosphamide, Bortezomib (VELCADE), Dexamethasone
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Eastern Cooperative Oncology Group
Purpura, Idiopathic Thrombocytopenic Purpura
rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP
The project was undertaking by Qilu Hospital of Shandong University and other 13 well-known hospitals in China. In order to report the efficacy and safety of Recombinant Human thrombopoietin combining with Dexamethasone for the…
- Trial name
- NCT01734044
- Testing
- recombinant human thrombopoietin (rhTPO); dexamethasone, Dexamethasone
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Shandong University
Sudden Sensorineural Hearing Loss (SSNHL)
Intratympanic Injection of Dexamethasone With Hyaluronic Acid in Treatment of Sudden Sensorineural Hearing Loss
To evaluate efficacy of intratympanic injection of dexamethasone and hyaluronic acid mixture as a treatment modality in cases of sudden sensorineural hearing loss (SSNHL).
- Trial name
- NCT06878599
- Testing
- Hyaluronic Acid (HA), Dexamethasone
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Assiut University
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
This phase Ib trial tests the safety, side effects, and best dose of CC-92480 in combination with elotuzumab and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed)…
- Trial name
- NCT05981209
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Abdullah Khan
Multiple Myeloma
A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
This study will evaluate the safety and preliminary efficacy of venetoclax when combined with lenalidomide and dexamethasone for participants with newly diagnosed, active t(11;14) positive multiple myeloma (MM).
- Trial name
- NCT03785184
- Testing
- venetoclax, lenalidomide, dexamethasone
- Where
- 22 sites in United States, Australia and 2 more
- Sponsor
- AbbVie
Multiple Myeloma
Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate efficacy and safety of the combination regimen of bortezomib-bendamustine-dexamethasone in patients with relapsed or refractory multiple myeloma
- Trial name
- BBD (NCT01168804)
- Testing
- bendamustine plus bortezomib plus dexamethasone
- Where
- 8 sites in Austria, Czechia
- Volunteers
- 79 people
- Sponsor
- Austrian Forum Against Cancer
Multiple Myeloma
An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.
This is a Phase 1/2 study evaluating the safety and anti-tumor activity of PD 0332991 in combination with Velcade® [bortezomib] and dexamethasone in patients who have received at least one previous treatment for multiple myeloma.
- Trial name
- NCT00555906
- Testing
- Bortezomib, Dexamethasone, PD 0332991
- Where
- 19 sites in United States, Czechia and 1 more
- Volunteers
- 53 people
- Sponsor
- Pfizer
Amyloidosis
Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis
This randomized phase III trial is studying the side effects and how well giving induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation (ASCT) compared with ASCT alone in treating…
- Trial name
- NCT01998503
- Testing
- Bortezomib, dexamethasone, filgrastim
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Nanjing University School of Medicine
Osteoarthritis of the Knee
Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients
This trial is a Phase IIa, Randomized, Double blinded, Placebo controlled, Dose finding Study to investigate the safety and efficacy of TLC599 in subjects with osteoarthritis of the knee.
- Trial name
- NCT03005873
- Testing
- TLC599 LD group, Normal Saline, TLC599 HD group
- Where
- 13 sites in Australia, Taiwan
- Volunteers
- 76 people
- Sponsor
- Taiwan Liposome Company
Immune Thrombocytopenia
Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia
The purpose of this study is to determine the response rate and response duration with the combination of low-dose rituximab, eltrombopag and high-dose dexamethasone.
- Trial name
- NCT02834286
- Testing
- Rituximab, Eltrombopag, Dexamethasone
- Where
- Mexico
- Volunteers
- 15 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Rhinosinusitis, Rhinitis
Safety and Efficacy of DSM 32444 Postbiotic in the Treatment of Acute Rhinosinusitis
Rhinitis is a type of upper respiratory infection with a common nasal pathology especially in Southeast Asia, which is characterized by the presence of one or more of the following symptoms: itchy nose, sneezing, runny nose, and…
- Trial name
- NCT05999955
- Testing
- Neomycin/ Dexameythasone/Xylometazoline, Bacillus subtilis DSM32444
- Where
- Vietnam
- Volunteers
- 60 people
- Sponsor
- Huro Biotech Joint Stock Company
Clinically Significant Macular Edema Due to Diabetes Mellitus
Anti-VEGF Therapy Versus Dexamethasone Implant for DME
We look at a randomized comparative study of 2 FDA approved anti-VEGF agents(aflibercept and ranibizumab) and see how they compare against the dexamethasone implant for phakic as well as pseudophakic eyes with treatment naive…
- Trial name
- NCT03999125
- Testing
- Aflibercept,, Ranibizumab Injection, Ozurdex Drug Implant Product
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Sudhalkar Eye Hospital
Extranodal NK/T-cell Lymphoma, Nasal Type
MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma
Extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type, is a distinct and heterogeneous histopathologic subtype of non-Hodgkin lymphoma (NHL), accounting for 5%~10%.
- Trial name
- NCT02631239
- Testing
- Methotrexate, Etoposide, Dexamethasone
- Where
- China
- Volunteers
- 256 people
- Sponsor
- Ruijin Hospital
Rheumatic Fever, Sydenham Chorea
TREAT-SC: Early, Short Course Oral Dexamethasone for the Treatment of Sydenham Chorea in Children
The purpose of this study is to find out whether an early three-day course of an oral steroid medication (dexamethasone) can improve the physical and mental recovery and wellbeing for children with Sydenham's chorea.
- Trial name
- TREAT-SC (NCT06259006)
- Testing
- Dexamethasone Oral
- Where
- 17 sites in Australia, New Zealand
- Volunteers
- 80 people
- Sponsor
- Starship Child Health, Te Toka Tumai Auckland
Multiple Myeloma
Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)
This is a phase III, multicenter, prospective with a clinical benefit, open-label and randomized study to compare two different treatments : Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) versus Velcade (Bortezomib)…
- Trial name
- IFM2013-04 (NCT01971658)
- Testing
- Thalidomide®, Cyclophosphamide, Velcade®
- Where
- 62 sites in France
- Volunteers
- 358 people
- Sponsor
- Nantes University Hospital
Multiple Myeloma
Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients
The aim of this non-interventional study is to collect primarily the percentage of patients who receive the full dose of dexamethasone (20 or 40 mg orally once daily on days 1, 8, 15 and 22 of the repetitive 28-day cycles, 20 mg…
- Trial name
- NCT03001804
- Where
- 12 sites in Austria
- Volunteers
- 29 people
- Sponsor
- Celgene